Navigation Links
Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
Date:8/16/2011

SAN DIEGO, Aug. 16, 2011 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that its Investigational New Drug (IND) application for ME-143 (formerly NV-143), the Company's lead NADH oxidase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The Company plans to initiate a Phase I clinical trial of intravenous ME-143 by September.

"This IND represents a significant milestone for Marshall Edwards and, more importantly, a critical step forward in the development of a drug candidate that we believe has the potential to significantly improve the treatment of patients with cancer," said Daniel P. Gold, Ph.D., President and Chief Executive Officer of Marshall Edwards. "We are excited to get back into the clinic and are working diligently to initiate a Phase I trial of ME-143 as soon as possible."

ME-143 was derived from an isoflavone technology platform that has generated a number of compounds with anti-proliferative activity against tumor cells in laboratory studies. In pre-clinical studies, ME-143 has demonstrated anti-tumor activity against a number of tumor cell lines, including breast, colorectal and ovarian. In addition to broad single-agent activity, ME-143 has also shown an ability to enhance the cytotoxic effects of chemotherapy in pre-clinical studies.

Marshall Edwards owns exclusive worldwide rights to ME-143.

About Marshall Edwards

Marshall Edwards, Inc. (Nasdaq: MSHL) is a San Diego-based oncology company focused on the clinical development of novel anti-cancer therapeutics. The Company's lead programs focus on two families of small molecules that result in the inhibition of tumor cell metabolism. The fir
'/>"/>

SOURCE Marshall Edwards, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
2. Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
3. Marshall Edwards Announces Closing of Asset Purchase Agreement With Novogen
4. Marshall Edwards Announces Private Placement
5. Marshall Edwards Announces Publication of Phase II Clinical Trial Results Highlighting Activity of Intravenous Phenoxodiol
6. Marshall Edwards Receives Positive Response From NASDAQ
7. Marshall Edwards to Host Annual Meeting of Stockholders
8. Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing
9. Marshall Edwards Announces Presentation of New Data Showing Activity in Chemotherapy-Resistant Ovarian Cancer Cells
10. Medical Device Consultants, Inc. Welcomes Brian Edwards, Senior Regulatory Staff Consultant
11. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... BioLineRx (NASDAQ: BLRX ; ... identifying, in-licensing and developing promising therapeutic candidates, today ... offering of American Depositary Shares ("ADSs"), each representing ... the ADSs in the offering are to be ... is acting as sole book-running manager for the ...
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März ... Gates Stiftung und das deutsche biopharmazeutische Unternehmen ... 46 Millionen Euro (52 Millionen US-Dollar) in ... Bereich der medizinisch angewandten Messenger-RNA (mRNA). Auf ... Ansätze zur Behandlung von Krankheiten und zum ...
(Date:3/5/2015)... March 5, 2015 CANTEL MEDICAL CORP. (NYSE: ... quarter ended January 31, 2015 on Thursday, March 12 before ... the results at 11:00 AM ET. To ... to 10 minutes before the beginning of the call. If ... call will be available from Thursday, March 12, 2015 through ...
Breaking Medicine Technology:BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 2BioLineRx Announces Underwritten Public Offering of its American Depositary Shares 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... Life Technologies Corporation (NASDAQ: LIFE) today ... revolutionary platform that eliminates the complexity of fluorescence microscopy ... their technical expertise.  A high-quality image can be captured ... the platform,s printer or downloaded and e-mailed to serve ...
... SAN DIEGO, Nov. 28, 2011 OncoSec Medical ... advanced-stage OMS ElectroOncology therapies to treat skin cancer ... Punit Dhillon, President and CEO, will be presenting ... Conference in New York City. (Logo: ...
Cached Medicine Technology:Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 2Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 3Life Technologies Makes Fluorescence Microscopy Accessible to All Scientists 4OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference 2
(Date:3/6/2015)... 06, 2015 Truly Nolen, the largest ... announce the grand opening of their first independently-owned and ... down to the Fort Mill – Rock Hill, SC ... 27th, 2015 at their new location. , ... of collective experience in the pest control industry. Locally ...
(Date:3/6/2015)... In a new study conducted at a Warsaw hospital, a ... was their first mesothelioma symptom. Surviving Mesothelioma has just posted ... read it now. , Doctors at the Central Clinical ... mesothelioma patients between 2006 and 2012 and found that ... first prompted them to see a doctor. For some, shoulder ...
(Date:3/6/2015)... March 06, 2015 The Gluten-Free ... Celiac Association, is pleased to announce that Dufflet ... Rosenberg, has expanded their product line of gluten-free ... as scrumptious and as satisfying as any of ... scratch, and never contains hydrogenated fats or oils, ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 FCPX developers ... from Pixel Film Studios. , “Pro3rd Hue is a lower ... Austin, CEO of Pixel Film Studios. “Blurring the line between ... , Pro3rd Hue is a set of 30 customizable lower ... X. With Pro3rd Hue, FCPX users can complement any design ...
(Date:3/6/2015)... The producers of Health Briefs TV are ... and vicinity. This is a city which is full of ... outdoor activities. It is also a city where healthcare is ... call the city home and provide care from the nearby ... program will be broadcast on CBS KLEW-TV during the month. ...
Breaking Medicine News(10 mins):Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:New Report Reveals Shoulder Pain Could Signal Early Mesothelioma, According to Surviving Mesothelioma 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:The Health Briefs TV Show to Air in Spokane, Washington 2
... only be healthy to the body but also helps smokers ... milk, water, fruits and vegetables worsened the taste of cigarettes, ... to the scientists. ,The findings could lead ... gum or lozenge that makes cigarettes less palatable, said lead ...
... in the US has pledged to spend over 500 million ... obesity// . ,The announcement by the Robert Wood ... public health initiatives ever tried by private philanthropy. ... the country in terms of morbidity and mortality and economically,” ...
... with mysterious medicinal properties due to their unique ability ... been used to fight topical pain, headaches and even ... also being used to treat common allergy symptoms. ... in hot peppers, there are four other Capsaicinoids that ...
... to doctors of Indian origin who are unable to find ... to changes in immigration rules. // ,Thousands of ... it difficult for non-European Union doctors to find employment in ... have since been the subject of litigation. ...
... the state to provide better healthcare to its people. // ... Government Dental College at Rohtak town in Haryana, Chief Minister ... would help in providing better healthcare facilities for people of ... funds would not be allowed to come in the way ...
... developed a test that can tell if a person is ... , Duke University researchers led by John Chute, ... technology to scan thousands of genes in the DNA of ... poisoning. ,Says Chute: "The goal would ...
Cached Medicine News:Health News:Diet May Play Vital Role to Help Smokers Quit 2Health News:500 Million US Dollars to Fight Childhood Obesity 2Health News:Spicy Pepper Remedy Equalizes Spring Pollen Allergies 2Health News:India Assures Help to Doctors of Indian Origin 2Health News:Gene Study To Reveal Radiation Poisoning 2
... Granular, free-flowing powder EEO(-m r ): less than ... than or equal to 35.5C Remelt Point (3%): ... greater than or equal to 600 gm/cm 2 ... equal to 1500 gm/cm 2 Moisture: 7% ...
... ≤ 500 mg/kg sulfate (SO 4 ) ≤ 1000 ... 5 mg/kg Co ≤ 5 mg/kg Cr ≤ 5 ... K ≤ 50 mg/kg Mg ≤ 50 mg/kg Mn ... 5 mg/kg Pb ≤ 5 mg/kg Zn ≤ 5 ...
... sulfate (SO 4 ) ≤ 6000 mg/kg Cation traces: ... ≤ 10 mg/kg Cr ≤ 10 mg/kg Cu ≤ ... mg/kg Mg ≤ 10 mg/kg Mn ≤ 10 mg/kg ... ≤ 10 mg/kg Zn ≤ 10 mg/kg Special ...
... Anion traces: chloride (Cl) ≤ 500 mg/kg sulfate (SO ... 500 mg/kg Cd ≤ 5 mg/kg Co ≤ 5 ... Fe ≤ 10 mg/kg K ≤ 5 mg/kg Mg ... 2000 mg/kg Ni ≤ 5 mg/kg Pb ≤ 5 ...
Medicine Products: